Hypoxia PET/CT imaging: Implications for radiation oncology

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 54, Issue 5, 2010, Pages 500-509

  Arabi, M ^a   Piert, M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cell hypoxia; Neoplasms; Radiation

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; COPPER DERIVATIVE; ETANIDAZOLE; FLUORODEOXYGLUCOSE F 18; FLUOROETANIDAZOLE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

CANCER RADIOTHERAPY; CELL HYPOXIA; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MEASUREMENT; NON INVASIVE PROCEDURE; OXYGEN TENSION; OXYGEN TRANSPORT; PATHOPHYSIOLOGY; PREDICTIVE VALIDITY; RADIATION DOSE DISTRIBUTION; RADIOSENSITIZATION; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

CELL HYPOXIA; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION ONCOLOGY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79251481188     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Vanderkooi JM, Erecinska M, Silver IA. Oxygen in mammalian tissue: methods of measurement and affinities of various reactions. Am J Physiol 1991;260(6 Pt 1):C1131-50.
2. Schumacker PT, Samsel RW. Oxygen delivery and uptake by peripheral tissues: physiology and pathophysiology. Crit Care Clin 1989;5:255-69.
3. Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med 1999;26.95-109.
4. Piert M, Machulla HJ, Becker G, Aldinger P, Winter E, Bares R. Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
5. nd edition. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 464-71.
6. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-54.
7. Lehmann S, Stiehl DP, Honer M, Dominietto M, Keist R, Kotevic I et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A 2009;106:14004-9.
8. Semenza GL. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J Lab Clin Med 1998;131:207-14.
9. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
10. Borgland SL, Parkinson FE. Effect of adenosine receptor agonists on release of the nucleoside analogue [3H]formycin B from cultured smooth muscle DDT1 MF-2 cells. Eur J Pharmacol 1998;346:339-44.
11. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28(2 Suppl 8):36-41.
12. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(4 Suppl):S62-7.
13. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63:25-36.
14. Kumar P. Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 2000;37(4 Suppl 6):4-8.
15. Jorgensen TJ. Enhancing radiosensitivity: targeting the DNA repair pathways. Cancer Biol Ther 2009;8:665-70.
16. Rengan R, Cengel KA, Hahn SM. Clinical target promiscuity: lessons from ras molecular trials. Cancer Metastasis Rev 2008;27:403-14.
17. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39. (Pubitemid 47101660)
18. West CM, Davidson SE, Roberts SA, Hunter RD. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer 1993;68:819-23.
19. Chapman JD, Dugle DL, Reuvers AP, Meeker BE, Borsa J. Letter: Studies on the radiosensitizing effect of oxygen in Chinese hamster cells. Int J Radiat Biol Relat Stud Phys Chem Med 1974;26: 383-9.
20. Palcic B, Skarsgard LD. Reduced oxygen enhancement ratio at low doses of ionizing radiation. Radiat Res 1984;100:328-39.
21. Williams KJ, Telfer BA, Xenaki D, Sheridan MR, Desbaillets I, Peters HJ, et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005;75:89-98.
22. Makin G, Hickman JA. Apoptosis and cancer chemotherapy. Cell Tissue Res 2000;301:143-52.
23. 2 tension measurements. Cancer Res 1991;51:3316-22.
24. Nordsmark M. Direct measurements of tumor-tissue pO2. A way of selecting patients for hyperoxic treatment. Strahlenther Onkol 1996;172 Suppl 2:8-9.
25. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
26. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev 2008;34:313-27.
27. Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
28. Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ et al. CA LX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 2006;12:6421-31. (Pubitemid 44799714)
29. Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005;49:325-35.
30. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727-35.
31. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. Oral Oncol 2008;44:335-44.
32. Picchio M, Beck R, Haubner R, Seidl S, Machulla HJ, Johnson TD et al. Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by 18F-FAZA and 125I-Gluco-RGD Autoradiography. J Nucl Med 2008;49:597-605.
33. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 2:129S-48S.
34. Maeda K, Osato T, Umezawa H. A new antibiotic, azomycin. J Antibiot (Tokyo) 1953;6:182.
35. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001;49:1171-82.
36. Chapman JD. Hypoxic sensitizers - implications for radiation therapy. N Engl J Med 1979;301:1429-32.
37. Mc Clelland RA. Molecular interactions and biological effects of the products of reduction of nitroimidazoles. In: Adams GE, Breccia A, Fiedlen EN, Wardman P, eds. NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes. New York: Plenum Press; 1990:125-36.
38. Machulla H-J. Imaging of hypoxia: Tracer developments. Dordrecht; Boston, Mass: Kluwer Academic; 1999.
39. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-Fluoromisonidazole. Semin Nucl Med 2007;37:451-61.
40. Rajendran JG, Hendrickson KR, Spence AM, Muzi M, Krohn KA, Mankoff DA. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006;33 Suppl 13:44-53. (Pubitemid 44139193)
41. 18F]-2-fluoro-2′- deoxiglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 2004;180:616-22.
42. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007;7:113.
43. Rasey J, Koh W, Evans M, Peterson L, Lewellen T, Graham M et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;24:417-28.
44. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245-52.
45. Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623-30.
46. Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 2004,64:3350-67
47. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60.
48. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005;32:1384-91. (Pubitemid 41746841)
49. 18F]fluoroery- thronitroimidazole PET. J Nucl Med 2001;42:1643-52.
50. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59:971-82.
51. Gronroos T, Bentzen L, Marjamaki P, Murata R, Horsman MR, Keiding S et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004;31:513-20.
52. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999;40:1072-9.
53. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ. Forsback S et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008;49:1944-51.
54. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, Larson S et al. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging 2004;31:117-28.
55. Riedl CC, Brader P, Zanzonico P, Reid V, Woo Y, Wen B et al. Tumor hypoxia imaging in orthotopic liver rumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging 2008;35:39-46. (Pubitemid 350234134)
56. 18F-Fluoroazomycin Arabinoside. J Nucl Med 2005;46:106-13.
57. Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA - first small animal PET results. J Pharm Pharm Sci 2007;10:203-11.
58. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Label Comp Radiopharmaceuticals 1999;42:3-16.
59. Souvatzoglou M, Roeper B, Grosu A, Machulla H-J, Picchio M, Beck R et al. Tumor hypoxia imaging with 18F-FAZA in head&neck cancer. A pilot study. J Nucl Med 2005;46(Suppl 2):43P.
60. Postema EJ, McEwan AJ, Riauka TA, Kumar P, Richmond DA, Abrams DN et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[(18)F]- fluoroarabinofuranosyl)-2-nitroimidazole ((18)F-FAZA). Eur J Nucl Med Mol Imaging 2009 [Epub ahead of print].
61. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60.
62. Dearling JL, Lewis JS, Mullen GE, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J Biol Inorg Chem 2002;7:249-59.
63. 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003;55:1233-8.
64. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging 2009;53:193-200.
65. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493-502.
66. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006;47:989-98. (Pubitemid 46939952)
67. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. J Med Chem 2005;48:2985-92.
68. Piert M, Machulla HJ, Picchio M, Reischl G, Ziegler S, Kumar P et al. Hypoxia-specific tumor imagine with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106-13.
69. Hoogsteen IJ, Pop LA, Marres HA, Merkx MA, van den Hoogen FJ, van der Kogel AJ et al. Oxygen-modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2006;64:83-9.
70. Kaanders JH, Pop LA, Marres HA, Bruaset I, van den Hoogen FJ, Merkx MA et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52: 769-78.
71. Bennett M, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer Treat Rev 2008;34:577-91.
72. Kagerud A, Klintenberg C, Lund N, Peterson HI. Influence of tocopherol on tumour cell oxygenation. Cancer Lett 1978;5:185-9.
73. Stratford IJ, Workman P. Bioreductive drugs into the next millennium. Anticancer Drug Des 1998;13:519-28.
74. Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem 2001;36(7-8):577-95.
75. Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007;48:973-80.
76. Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTARD: a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010;28:2989-95.
77. Papadopoulou MV, Bloomer WD. NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 2003;9:5714-20.
78. Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U et al. Positron Emission Tomography for Radiation Treatment Planning. Strahlenther Onkol 2005;181:483-99.
79. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S et al. Towards multidimensional radiotherapy (MD-CRD: biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000;47:551-60.
80. Souvatzoglou M, Grosu AL, Roper B, Krause BJ, Beck R, Reischl G et al. Tumour hypoxia imaging with [(18)F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007;34:1566-75.
81. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006;12:5435-41.
82. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005;5:152.
83. 60Cu- ATSM. Eur J Nucl Med Mol Imaging 2003;30:844-50.
84. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J et al. Tumor Hypoxia detected by positron emission tomography with (60)Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008;51:1641-8
85. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008;49:201-5.
86. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:235-42.
87. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J et al. The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on (18)F-FMISO Positron Emission Tomography. Int J Radiat Oncol Biol Phys 2008;70:1219-28.
88. 18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 2003;30:695-704.
89. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC et al. Prospective Trial Incorporating PreVMid-Treatment t(18)F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009.
90. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M et al. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 2007;83:406-10.
91. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys 2007;68:515-21.
92. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S et al. Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys 2007;70:2-13.
93. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V et al. Hypoxia Imaging With FAZA-PET and Theoretical Considerations With Regard to Dose Painting for Individualization of Radiotherapy in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2007;69:541-51.
94. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009;50:1020-7.
95. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010 [Epub ahead of print].
96. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007;68:291-300.
97. Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, Cristini V. An integrated computational/experimental model of tumor invasion. Cancer Res 2006;66:1597-604.
98. Bottaro DP, Liotta LA. Cancer: Out of air is not out of action. Nature 2003;423:593-5.
99. Sovik A, Malinen E, Bruland OS, Bentzen SM, Olsen DR. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Phys Med Biol 2007;52:499-513.
100. Petit SF, Dekker AL, Seigneuric R, Murrer L, van Riel NA, Nordsmark M et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol 2009;54:2179-96.